Study Summary
This trial is testing an intervention to help improve quality of life and reduce lymphoma-related worries for survivors.
- Lymphoma
- Survivorship
Treatment Effectiveness
Study Objectives
3 Primary · 7 Secondary · Reporting Duration: Up to 6 months
Trial Safety
Trial Design
3 Treatment Groups
Clinicians Interviews
1 of 3
UPLYFT Pilot
1 of 3
Lymphoma Survivors Field Test
1 of 3
Experimental Treatment
74 Total Participants · 3 Treatment Groups
Primary Treatment: Pilot of UPLYFT with Lymphoma Survivors · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 12 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many participants are partaking in this experiment?
"Affirmative. According to clinicaltrials.gov, this experiment is actively recruiting patients with a posted date of February 8th 2022 and an amended posting on March 14th 2022. The study seeks 74 participants at one medical centre." - Anonymous Online Contributor
What is the ultimate intent of this clinical inquiry?
"This clinical trial will assess the feasibility of program session completion rate over a 6 month period. Secondary parameters such as pre-intervention to post-intervention changes in anxiety (as measured by Hospital and Anxiety Scale) and psychological inflexibility (as assessed via Acceptance and Action Questionnaire-II) are also being evaluated, with an acceptability threshold set at ≤ 10% disenrollment rate." - Anonymous Online Contributor
Is enrollment currently open for this research study?
"This trial, which was initially listed on February 8th 2022, is still open for patient recruitment. Accordingly, it has been updated as recently as March 14th 2022." - Anonymous Online Contributor